Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Hepatitis C Drugs MK-5172, ABT-450 Show Promise for All-Oral Regimens

November 12, 2012

Merck & Co., Gilead Sciences Inc, Abbott Laboratories, and other companies are working to come up with all-oral hepatitis C treatments. So far, standard treatments for hepatitis C include interferon, but interferon can be difficult for patients to tolerate. Merck reports that during a midstage clinical trial of an experimental Merck treatment, the drug, MK-5172, suppressed hepatitis C virus in most patients. The drug study also included the use of injected interferon. MK-5172 appears to be more potent than another Merck drug, Victrelis. Merck plans new studies of MK-5172 as an all-oral hepatitis C treatment without interferon.

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement